Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis

BACKGROUND: Several immuno-oncology (IO) agents targeting programmed death-1 or programmed death-ligand 1 (PD-1/L1) are approved second-line therapy options for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) previously treated with platinum-based chemotherapy or first-lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hepp, Zsolt, Shah, Sonali N, Smoyer, Karen, Vadagam, Pratyusha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394179/
https://www.ncbi.nlm.nih.gov/pubmed/33355035
http://dx.doi.org/10.18553/jmcp.2020.20285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394179/
https://www.ncbi.nlm.nih.gov/pubmed/33355035
http://dx.doi.org/10.18553/jmcp.2020.20285

Ejemplares similares